NCI-2019-04523A Phase 1/2 study of IDE196 in patients with solid tumors harboring GNAQ/11 mutations or PRKC fusionsFor more information about the trial, click the link below:https://clinicaltrials.gov/ct2/show/NCT03947385Clinical Trial Site: ColumbiaTo see all available clinical trials click here.
A Phase 1/2 study of IDE196 in patients with solid tumors harboring GNAQ/11 mutations or PRKC fusionsFor more information about the trial, click the link below:https://clinicaltrials.gov/ct2/show/NCT03947385Clinical Trial Site: ColumbiaTo see all available clinical trials click here.
NCI-2024-07005A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial...
NCI-2024-02382A Platform Study of RAS(ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC) This is a platform...
NCI-2024-06081A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd), A B7-H3 ANTIBODY-DRUG CONJUGATE (ADC), IN COMBINATION WITH...
Comments